- Home
- ACIU vs NRO Comparison
ACIU vs NRO Comparison
Compare ACIU & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIU | NRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 199.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIU | NRO |
|---|---|---|
| Price | $3.04 | $2.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 239.4K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,482,957.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $738.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $2.51 |
| 52 Week High | $4.00 | $3.45 |
Technical Indicators
Market Signals| Indicator | ACIU | NRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 29.48 |
| Support Level | $2.54 | $2.96 |
| Resistance Level | $3.45 | $3.06 |
| Average True Range (ATR) | 0.30 | 0.03 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 38.10 | 5.00 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").